WO2007111940A3 - Regimens for immunisation with meningococcal conjugates - Google Patents

Regimens for immunisation with meningococcal conjugates Download PDF

Info

Publication number
WO2007111940A3
WO2007111940A3 PCT/US2007/007115 US2007007115W WO2007111940A3 WO 2007111940 A3 WO2007111940 A3 WO 2007111940A3 US 2007007115 W US2007007115 W US 2007007115W WO 2007111940 A3 WO2007111940 A3 WO 2007111940A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunisation
regimens
meningococcal conjugates
administered
months
Prior art date
Application number
PCT/US2007/007115
Other languages
French (fr)
Other versions
WO2007111940A2 (en
Inventor
Lisa Danzig
Original Assignee
Novartis Ag
Lisa Danzig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38327015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007111940(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK07753720.7T priority Critical patent/DK2004225T3/en
Priority to US12/225,501 priority patent/US10543265B2/en
Priority to AU2007229449A priority patent/AU2007229449A1/en
Priority to ES07753720T priority patent/ES2383209T3/en
Priority to SI200730954T priority patent/SI2004225T1/en
Priority to NZ572054A priority patent/NZ572054A/en
Priority to PL07753720T priority patent/PL2004225T3/en
Application filed by Novartis Ag, Lisa Danzig filed Critical Novartis Ag
Priority to CA2646993A priority patent/CA2646993C/en
Priority to AT07753720T priority patent/ATE554788T1/en
Priority to EP07753720A priority patent/EP2004225B1/en
Publication of WO2007111940A2 publication Critical patent/WO2007111940A2/en
Publication of WO2007111940A3 publication Critical patent/WO2007111940A3/en
Priority to US12/287,225 priority patent/US10828361B2/en
Priority to US16/716,638 priority patent/US10881721B2/en
Priority to US17/082,415 priority patent/US20210060151A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/36—Neisseria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.
PCT/US2007/007115 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates WO2007111940A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP07753720A EP2004225B1 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
PL07753720T PL2004225T3 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
AU2007229449A AU2007229449A1 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
ES07753720T ES2383209T3 (en) 2006-03-22 2007-03-22 Regimens for immunization with meningococcal conjugates
CA2646993A CA2646993C (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
NZ572054A NZ572054A (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
US12/225,501 US10543265B2 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
DK07753720.7T DK2004225T3 (en) 2006-03-22 2007-03-22 Programs for vaccination with meningococcal conjugates
SI200730954T SI2004225T1 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
AT07753720T ATE554788T1 (en) 2006-03-22 2007-03-22 SCHEMATICS FOR IMMUNIZATION WITH MENINGOCOCCAL CONJUGATES
US12/287,225 US10828361B2 (en) 2006-03-22 2008-10-06 Regimens for immunisation with meningococcal conjugates
US16/716,638 US10881721B2 (en) 2006-03-22 2019-12-17 Regimens for immunisation with meningococcal conjugates
US17/082,415 US20210060151A1 (en) 2006-03-22 2020-10-28 Regimens for immunisation with meningococcal conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78523406P 2006-03-22 2006-03-22
US60/785,234 2006-03-22

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/225,501 A-371-Of-International US10543265B2 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
US12/287,225 Continuation-In-Part US10828361B2 (en) 2006-03-22 2008-10-06 Regimens for immunisation with meningococcal conjugates
US16/716,638 Continuation US10881721B2 (en) 2006-03-22 2019-12-17 Regimens for immunisation with meningococcal conjugates

Publications (2)

Publication Number Publication Date
WO2007111940A2 WO2007111940A2 (en) 2007-10-04
WO2007111940A3 true WO2007111940A3 (en) 2007-11-15

Family

ID=38327015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007115 WO2007111940A2 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates

Country Status (14)

Country Link
US (4) US10543265B2 (en)
EP (2) EP2004225B1 (en)
AT (1) ATE554788T1 (en)
AU (1) AU2007229449A1 (en)
CA (1) CA2646993C (en)
CY (1) CY1112920T1 (en)
DK (1) DK2004225T3 (en)
ES (2) ES2670231T3 (en)
NZ (1) NZ572054A (en)
PL (1) PL2004225T3 (en)
PT (1) PT2004225E (en)
SI (1) SI2004225T1 (en)
TR (1) TR201807355T4 (en)
WO (1) WO2007111940A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1800385B (en) 2000-02-28 2010-06-02 启龙有限公司 Hybrid expression of neisserial proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
TR201807355T4 (en) * 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa Immunization regimens with meningococcal conjugates.
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP5668049B2 (en) * 2009-03-24 2015-02-12 ノバルティス アーゲー Combination of meningococcal factor H binding protein and pneumococcal saccharide conjugate
HUE052850T2 (en) 2010-08-23 2021-05-28 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
KR101763625B1 (en) 2012-03-09 2017-08-01 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
ES2685894T3 (en) 2013-03-08 2018-10-15 Pfizer Inc. Immunogenic fusion polypeptides
KR20150121265A (en) 2013-03-18 2015-10-28 글락소스미스클라인 바이오로지칼즈 에스.에이. Method of treatment
RU2662968C2 (en) 2013-09-08 2018-07-31 Пфайзер Инк. Immunogenic composition for neisseria meningitidis (options)
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
CN104998255B (en) * 2015-06-30 2018-08-28 北京祥瑞生物制品有限公司 New A CYW135 group meningitis cocci combined vaccines and preparation method thereof
CN109890413B (en) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 Neisseria meningitidis vaccine
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US20030068336A1 (en) * 2001-01-23 2003-04-10 Ryall Robert P. Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2005000345A2 (en) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
NL8802046A (en) 1988-08-18 1990-03-16 Gen Electric POLYMER MIXTURE WITH POLYESTER AND ALKANE SULFONATE, OBJECTS THEREFORE.
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0630260B1 (en) * 1991-03-12 2001-01-24 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Polysaccharide-protein conjugates
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
EP0652758B1 (en) 1992-06-18 2000-01-05 The President And Fellows Of Harvard College Diphtheria toxin vaccines
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69331495T2 (en) 1992-08-31 2002-10-31 Baxter Healthcare Sa VACCINE AGAINST NEISSERIA MENINGITIDIS GROUP C
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
ATE254475T1 (en) 1993-09-22 2003-12-15 Jackson H M Found Military Med METHOD FOR ACTIVATION OF SOLUBLE CARBOHYDRATES BY USING NEW CYANYLATION REAGENTS TO PRODUCE IMMUNOGENIC CONSTRUCTS
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
CA2221511C (en) 1995-06-07 2013-01-08 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
ES2325301T3 (en) 1995-06-23 2009-09-01 Glaxosmithkline Biologicals S.A. VACCINE COMPOSITION THAT INCLUDES A CONJUGATED POLISACARIDE ANTIGEN, ADSORBED ON ALUMINUM PHOSPHATE.
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6403306B1 (en) 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
DE69826851T2 (en) 1997-04-24 2005-02-10 Henry M. Jackson Foundation For The Advancement Of Military Medicine COUPLING UNMODIFIED PROTEINS TO HALOACYL OR DIHALOACYL-DERIVATED POLYSACCHARIDES FOR THE PREPARATION OF PROTEIN POLYSACCHARIDE VACCINES
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0994723A1 (en) 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
EP2226336B1 (en) 1997-12-23 2016-10-19 Pfizer Ireland Pharmaceuticals Bacterial capsular polysaccharide for use as vaccines or for linking to proteins in conjugate vaccines
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU771330B2 (en) 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
PL203917B1 (en) 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
EP2292263A3 (en) 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stabilizing biological molecules upon lyophilization
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
PE20020126A1 (en) 2000-06-29 2002-04-27 Smithkline Beecham Biolog VACCINE COMPOSITION
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1490409B1 (en) 2002-03-26 2008-12-31 Novartis Vaccines and Diagnostics S.r.l. Modified saccharides having improved stability in water
MXPA04011249A (en) 2002-05-14 2005-06-06 Chiron Srl Mucosal vaccines with chitosan adjuvant and meningococcal antigens.
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
BRPI0410341B8 (en) * 2003-05-07 2021-05-25 Sanofi Pasteur Inc polysaccharide-protein conjugates derivatized from multivalent meningococci and vaccine
EP2851088A1 (en) * 2003-06-23 2015-03-25 Baxter International Inc. Vaccines against group Y Neisseria meningitidis and meningoccal combinations thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
RU2379052C2 (en) 2004-04-30 2010-01-20 Чирон С.Р.Л. Meningococcal conjugate vaccination
EP2351582A1 (en) 2004-08-30 2011-08-03 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2611960C (en) * 2005-06-27 2015-05-05 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising n.meningitidis capsular saccharide conjugates
JP5135220B2 (en) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー Multiple vaccinations including serogroup C meningococcus
TR201807355T4 (en) * 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa Immunization regimens with meningococcal conjugates.
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US20030068336A1 (en) * 2001-01-23 2003-04-10 Ryall Robert P. Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2005000345A2 (en) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORROW RAY ET AL: "Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom.", INFECTION AND IMMUNITY, vol. 71, no. 10, October 2003 (2003-10-01), pages 5549 - 5555, XP002446851, ISSN: 0019-9567 *
LEACH AMANDA ET AL: "Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine", JOURNAL OF INFECTIOUS DISEASES, vol. 175, no. 1, 1997, pages 200 - 204, XP008082381, ISSN: 0022-1899 *

Also Published As

Publication number Publication date
TR201807355T4 (en) 2018-06-21
ATE554788T1 (en) 2012-05-15
PT2004225E (en) 2012-05-30
DK2004225T3 (en) 2012-08-06
CY1112920T1 (en) 2016-04-13
US20080026002A1 (en) 2008-01-31
EP2357001A1 (en) 2011-08-17
SI2004225T1 (en) 2012-08-31
EP2357001B1 (en) 2018-03-07
AU2007229449A1 (en) 2007-10-04
EP2004225B1 (en) 2012-04-25
ES2383209T3 (en) 2012-06-19
US10881721B2 (en) 2021-01-05
US10543265B2 (en) 2020-01-28
CA2646993A1 (en) 2007-10-04
ES2670231T3 (en) 2018-05-29
NZ572054A (en) 2011-12-22
PL2004225T3 (en) 2012-09-28
US20200138932A1 (en) 2020-05-07
WO2007111940A2 (en) 2007-10-04
EP2004225A2 (en) 2008-12-24
US20210060151A1 (en) 2021-03-04
CA2646993C (en) 2016-01-26
US20090297553A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
WO2007111940A3 (en) Regimens for immunisation with meningococcal conjugates
WO2007071786A3 (en) Conjugate vaccines
WO2005105140A3 (en) Meningococcal conjugate vaccination
IL222346A (en) Immunogenic composition comprising at least two different n meningitides capsular saccharides, uses thereof and a vaccine comprising the same
ATE463261T1 (en) MENINGOCOCCAL CONJUGATE VACCINATION
WO2007026249A3 (en) Multiple vaccination including serogroup c meningococcus
WO2005105141A3 (en) Combined meningococcal conjugates with common carrier protein
WO2007116028A3 (en) Conjugate vaccines
AR058592A1 (en) VACCINE
WO2010067202A3 (en) Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2007142810A3 (en) Methods of using low-dose doxepin for the improvement of sleep
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
EP2364725A3 (en) Immunization method against neisseria meningitidis serogroups a and c
GB0408978D0 (en) Meningococcal fermentation for preparing conjugate vaccines
EP1791562A4 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2009143413A8 (en) Synergistic immunogenic fusion protein-polysaccharide conjugate
ZA200701675B (en) Multivalent meningococcal derivatized polysaccharideprotein conjugates and vaccine
WO2007083190A3 (en) Water insoluble helichrysum extract, process for preparing the same and uses thereof
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
MX2015013401A (en) Method of treatment.
WO2009108168A3 (en) Gold nanoparticle glycoconjugates for generating igg specific for the carbohydrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753720

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2646993

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007229449

Country of ref document: AU

Ref document number: 572054

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007753720

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007229449

Country of ref document: AU

Date of ref document: 20070322

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12225501

Country of ref document: US